CryoFreeze Wart and Skin Tag Remover

K243487 · Cryosurgery, Inc. · GEH · Mar 13, 2025 · General, Plastic Surgery

Device Facts

• Record ID: K243487
• Device Name: CryoFreeze Wart and Skin Tag Remover
• Applicant: Cryosurgery, Inc.
• Product Code: GEH · General, Plastic Surgery
• Decision Date: Mar 13, 2025
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 878.4350
• Device Class: Class 2
• Attributes: Therapeutic, Pediatric

Intended Use

The CryoFreeze Wart and Skin Tag Remover is intended for use in the over-the-counter treatment of common warts and plantar warts in adults and children age 4 years or older and over-the-counter treatment of skin tags in adults age 22 years or older.

Device Story

CryoFreeze is an OTC cryosurgical device for home use by laypersons to treat common warts, plantar warts, and skin tags. The device consists of a pressurized aerosol canister containing a mixture of dimethyl ether, propane, and isobutane, along with applicator swabs. Operation involves saturating an applicator swab with the cryogen and applying the foam tip directly to the lesion for 40 seconds. The extreme cold (-55°C) destroys the target tissue via localized freezing. The frozen tissue turns white and thaws over 20-40 seconds. The device is disposable after the cryogen is depleted. No special training or sterilization is required.

Clinical Evidence

No clinical data. Bench testing only. Comparative performance testing against the reference device (Verruca-Freeze H) evaluated output temperature, freeze charge hold time, and visual confirmation of ice ball formation, confirming equivalent performance.

Technological Characteristics

Cryosurgical unit; aerosol canister containing dimethyl ether, propane, and isobutane; foam-tipped applicators; disposable; non-sterile; home-use; operating temperature -55°C.

Indications for Use

Indicated for OTC treatment of common and plantar warts in adults and children ≥4 years, and skin tags in adults ≥22 years.

Regulatory Classification

Identification

(1) Cryosurgical unit with a liquid nitrogen cooled cryoprobe and accessories. A cryosurgical unit with a liquid nitrogen cooled cryoprobe and accessories is a device intended to destroy tissue during surgical procedures by applying extreme cold. (2) Cryosurgical unit with a nitrous oxide cooled cryoprobe and accessories. A cryosurgical unit with a nitrous oxide cooled cryoprobe and accessories is a device intended to destroy tissue during surgical procedures, including urological applications, by applying extreme cold. (3) Cryosurgical unit with a carbon dioxide cooled cryoprobe or a carbon dioxide dry ice applicator and accessories. A cryosurgical unit with a carbon dioxide cooled cryoprobe or a carbon dioxide dry ice applicator and accessories is a device intended to destroy tissue during surgical procedures by applying extreme cold. The device is intended to treat disease conditions such as tumors, skin cancers, acne scars, or hemangiomas (benign tumors consisting of newly formed blood vessels) and various benign or malignant gynecological conditions affecting vulvar, vaginal, or cervical tissue. The device is not intended for urological applications.

Predicate Devices

• Freeze 'n Clear Skin Clinic for Warts and Skin Tags (K211099)

Reference Devices

• Verruca-Freeze H (K243454)

Submission Summary (Full Text)

{0}------------------------------------------------

March 13, 2025

Image /page/0/Picture/1 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the FDA logo is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

CryoSurgery, Inc. Ronald Mcdow CEO and Medical Director 5829 Old Harding Pike Nashville, Tennessee 37205

Re: K243487

Trade/Device Name: CryoFreeze Wart and Skin Tag Remover Regulation Number: 21 CFR 878.4350 Regulation Name: Cryosurgical Unit And Accessories Regulatory Class: Class II Product Code: GEH Dated: February 12, 2025 Received: February 12, 2025

Dear Ronald Mcdow:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"

{1}------------------------------------------------

(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rue"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

{2}------------------------------------------------

Sincerely,

Image /page/2/Picture/3 description: The image shows a digital signature of James H. Jang. The signature includes the name "James H. Jang -S" on the left side of the image. On the right side, it states that the signature is digitally signed by James H. Jang -S, with a date of 2025.03.13 and a timestamp of 11:38:50 -04'00'.

Long Chen, Ph.D. Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

# Indications for Use

510(k) Number (if known) K243487

Device Name

CryoFreeze Wart and Skin Tag Remover

Indications for Use (Describe)

The CryoFreeze Wart and Skin Tag Remover is intended for use in the over-the-counter treatment of common warts and plantar warts in adults and children age 4 years or older and over-the-counter treatment of skin tags in adults age 22 years or older.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

X Over-The-Counter Use (21 CFR 801 Subpart C)

# CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image shows the logo for Cryosurgery, Inc. The logo is in blue and features a stylized letter C on the left. The words "RYOSURGERY, INC." are to the right of the C.

# 510(k) Summary

- 1. Submission Sponsor CryoSurgery, Inc. 5829 Old Harding Pike Nashville, TN 37205 [phone] [e-mail] 2. Contact Person Ronald McDow 5829 Old Harding Pike Nashville, TN 37205 [phone] 3. Date Prepared Updated 03/07/2025 4. Device Identification

| Trade / Proprietary Name | CryoFreeze Wart and Skin Tag Remover |
|--------------------------|----------------------------------------------|
| Common / Used Name | OTC Cryosurgical Device |
| Regulation | 878.4350 - Cryosurgical unit and accessories |
| Product Code | GEH |
| Class | 2 |

- 5. Predicate Device
6.

| Device Name | Freeze 'n Clear Skin Clinic for Warts and Skin Tags |
|-------------------|-----------------------------------------------------|
| 510(k) Number | K211099 |
| Regulation Number | 878.4350 - Cryosurgical unit and accessories |
| Product Code | GEH |
| Class | 2 |
| Reference Device | |
| Device Name | Verruca-Freeze H |
| 510(k) Number | K243454 |
| Regulation Number | 878.4350 - Cryosurgical unit and accessories |
| Product Code | GEH |
| Class | 2 |

# 7. Description of the Subject Device

The CryoFreeze Wart and Skin Taq Remover is an over-the-counter (OTC) cryotherapy device designed for the treatment of common, plantar warts, and skin tags. The device includes:

{5}------------------------------------------------

Image /page/5/Picture/1 description: The image shows the logo for Cryosurgery, Inc. The logo is blue and features a stylized letter "C" on the left side. To the right of the "C" is the text "RYOSURGERY, INC." The text is also in blue and is in a sans-serif font.

- A pressurized aerosol canister filled with a liquid mixture of the compressed gases dimethyl ether, ● propane, and isobutane
- Applicator swabs
- Detailed instructions, including illustrated descriptions

To use the device, the user must insert an applicator swab into the actuator, saturate the swab with cryogen, and apply the foam tip of the swab directly onto the lesion, holding it in place for 40 seconds. After removal, the frozen tissue will appear white and begin to thaw, typically taking 20-40 seconds.

The device is non-sterile and intended for home use by laypersons. No special training or sterilization is required for operation.

# 8. Indications for Use

The CryoFreeze Wart and Skin Tag Remover is intended for the counter treatment of common warts and plantar warts in adults and children age 4 years or older and over-the-counter treatment of skin tags in adults age 22 or older.

### 9. Technological Comparison

The subject device has the same technological characteristics as the predicate device. It shares the same intended use, mechanism of action, and design as the predicate device.

Additionally, the subject device has the same technological characteristics, mechanism of action, design as the reference device Verruca-Freeze H.

| Technological<br>Characteristics | Subject Device:<br>CryoFreeze Wart and Skin Tag<br>Remover | Predicate Device:<br>Freeze 'n Clear<br>Skin Clinic for Warts and Skin<br>Tags |
|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| Trade Name / Device Name | CryoFreeze™ Wart and Skin Tag<br>Remover | Skin Clinic Freeze 'n Clear for<br>Warts and Skin Tags |
| 510(k) Number | K243487 | K211099 |
| Indications for Use | The CryoFreeze Wart and Skin<br>Tag Remover is intended for use<br>in the over-the-counter treatment<br>of common warts and plantar<br>warts in adults and children age<br>4 years or older and over-the-<br>counter treatment of skin tags in<br>adults age 22 years or older. | The Freeze n' Clear Skin Clinic<br>for Warts and Skin Tags product<br>is intended for OTC treatment of<br>common warts, plantar warts,<br>and skin tags. |
| Cryogen Material | Mixture of dimethyl ether,<br>propane, and isobutane | Mixture of dimethyl ether,<br>propane, and isobutane |
| Freeze Temperature | -55°C | -55°C |
| Design | -Cryogen canister with attached<br>safety shield<br>-Foam-tipped applicators<br>-Disposable tweezers | -Cryogen canister with attached<br>safety shield<br>-Foam-tipped applicators<br>-Disposable tweezers |
| Mechanism of Action | Extreme cold destroys the target<br>tissue | Extreme cold destroys the target<br>tissue |

{6}------------------------------------------------

#### 510(k) Summary

Image /page/6/Picture/1 description: The image shows the logo for "Cryosurgery, Inc.". The logo is in blue and features a stylized "C" that is open on the right side. The text "RYOSURGERY, Inc." is to the right of the "C", with "RYOSURGERY" on the same line as the top of the "C" and "Inc." on the same line as the bottom of the "C".

CryoFreeze Wart and Skin Tag Remover K243487

| Treatment Procedure | Cryogen is dispensed into foam<br>applicator which is then applied<br>to the lesion for a specified<br>number of seconds. | |
|-------------------------------|---------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| | -Keep away from fire or flame<br>-Do not smoke while using the<br>product | -Keep away from fire or flame<br>-Do not smoke while using the<br>product |
| Storage and Safety Conditions | -Do not puncture or incinerate<br>canister | -Do not puncture or incinerate<br>canister |
| | -Do not expose to heat or store<br>at temperatures above 120°F. | -Do not expose to heat or store<br>at temperatures above 120°F. |
| | -Store at room temperature away<br>from heat | -Store at room temperature away<br>from heat |
| Disposal | Entire unit is disposable after<br>emptied of cryogen. | Entire unit is disposable after<br>emptied of cryogen. |
| Defined Operators | OTC for consumer use | OTC for consumer use |

### 10. Non-Clinical Performance Data

CryoFreeze Wart and Skin Tag Remover underwent comparative performance testing against the reference device, Verruca-Freeze H. The tests included output temperature of cryogen, freeze charge hold time, and visual confirmation of the ice ball. The comparison of test data confirmed that the subject device performs equivalently to the reference device.

11. Statement of Substantial Equivalence

Based on the information presented, it is concluded that the CryoFreeze Wart and Skin Tag Remover device is substantially equivalent to the predicate device Freeze 'n Clear Skin Clinic for Warts and Skin Tags.